Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: forbius.com
Global Number of Employees (Latest): -
Year Founded: 2011
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Formation Biologics Inc. operates as a clinical-stage protein engineering company that designs and develops bio therapeutics for the treatment of cancer and fibrotic diseases. It includes transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. Its products includes AVID100, AVID200, AVID300, and AVID400. It provides AVID100, which includes anti-EGFR targeting antibody-drug conjugate (ADC); AVID200, which includes isoform-selective TGF-β inhibitor; AVID300, which includes TGF-ß inhibitor, fibrosis, and subcutaneous formulation. Formation Biologics Inc. was formerly known as AvidBiologics Inc. Formation Biologics Inc. was founded in 2011 and is based in Austin, Texas with an additional office in Montreal, Canada. Formation Biologics Inc. operates as a subsidiary of Bristol-Myers Squibb Company.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
-
Net Debt
-
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Tikhomirov, Ilia A.
Chief Executive Officer, President and Director
Blattler, Walter A.
Chief Advisor of R&D and Director

Key Board Members
Name
Title
Allan, David G. P.
Chairman
Tikhomirov, Ilia A.
Chief Executive Officer, President and Director
Blattler, Walter A.
Chief Advisor of R&D and Director
Gruber, Joerg 
Director
Stiernholm, Bjorn Johan Niclas
Director
Tolcher, Anthony W.
Director
Underdown, Brian J.
Director


Primary Industry Classification
Biotechnology


Primary Office Location
701 Brazos Street Suite 930 | Austin, TX | 78701 | United States

Parent Company
Bristol-Myers Squibb Company (NYSE:BMY)

Prior Investors
HBM Healthcare Investments (Cayman) Ltd., HBM Healthcare Investments AG (SWX:HBMN), HBM Partners Ltd., Lumira Ventures (Brian Underdown), MaRs Discovery District, Investment Arm (Michelle McBane), MaRS Innovation Inc., MaRS Investment Accelerator Fund, Merck Lumira Biosciences Fund, Rosseau Asset Management Ltd.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-24-2020
Sep-21-2020
Merger/Acquisition
Target
Formation Biologics Inc.
Bristol-Myers Squibb Company (NYSE:BMY)
Lumira Ventures,MaRs Discovery District, Investment Arm
1,000.00
Oct-14-2019
Oct-14-2019
Private Placement
Target
Formation Biologics Inc.
HBM Partners Ltd.

-
May-15-2017
May-15-2017
Private Placement
Target
Formation Biologics Inc.
HBM Healthcare Investments AG (SWX:HBMN),HBM Partners Ltd.

-
May-14-2015
Cancelled
Private Placement
Target
Formation Biologics Inc.


1.09
Sep-29-2014
Sep-29-2014
Private Placement
Target
Formation Biologics Inc.
Lumira Ventures,MaRS Innovation Inc.,Rosseau Asset Management Ltd.,MaRs Discovery District, Investment Arm Buyer Funds:Merck Lumira Biosciences Fund

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-21-2020
M&A Transaction Closings
Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Formation Biologics Inc. for $1 billion.
Aug-24-2020
M&A Transaction Announcements
Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Formation Biologics Inc.
Aug-10-2020
Company Conference Presentations
Formation Biologics Inc. Presents at Piper Sandler Summer 2020 Private Company Showcase, Aug-10-2020 10:40 AM
Jul-14-2020
Company Conference Presentations
Formation Biologics Inc. Presents at Solebury Trout's Spring 2020 Private Company Showcase, Jul-14-2020
Jul-07-2020
Company Conference Presentations
Formation Biologics Inc. Presents at SVB Leerink Biopharma Private Company Connect, Jul-07-2020

M&A Advisors
Blake, Cassels & Graydon LLP, BofA Securities, Inc., Cooley LLP


Advisors
M&A Advisors
Blake, Cassels & Graydon LLP, BofA Securities, Inc., Cooley LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 26, 2023 05:11 AM
Formation Biologics Inc.
Forbius - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
21
GlobalData

Sep 15, 2023 01:10 AM
Formation Biologics Inc.
Forbius - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
28
GlobalData

Sep 14, 2023 09:28 PM
Formation Biologics Inc.
Forbius
Reports
55
GlobalData

Dec 16, 2022 02:47 AM
Formation Biologics Inc.
Forbius
Reports
55
GlobalData

Dec 10, 2022 02:45 AM
Formation Biologics Inc.
Forbius - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
28
GlobalData

Nov 22, 2022 11:06 PM
Formation Biologics Inc.
Forbius - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Sep 21, 2022 07:51 AM
Formation Biologics Inc.
Forbius
Reports
55
GlobalData

Sep 15, 2022 01:14 AM
Formation Biologics Inc.
Forbius - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
28
GlobalData

Aug 25, 2022 09:56 AM
Formation Biologics Inc.
Forbius - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Jun 20, 2022 04:14 AM
Formation Biologics Inc.
Forbius
Reports
55


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
AVID100 (Future), AVID200 (Future)

Key Board Members Details
Name
Title
Phone
Fax
Email
Allan, David G. P.
Chairman
-
-

Tikhomirov, Ilia A.
Chief Executive Officer, President and Director
-
-
ilia@avidbiologics.com
Blattler, Walter A.
Chief Advisor of R&D and Director
-
-

Gruber, Joerg 
Director
-
-

Stiernholm, Bjorn Johan Niclas
Director
(416) 595-0627
(416) 595-5835

Tolcher, Anthony W.
Director
-
-

Underdown, Brian J.
Director
(416) 213-4674
-
bunderdown@lumiracapital.com
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Tikhomirov, Ilia A.
Chief Executive Officer, President and Director
-
-
ilia@avidbiologics.com
Blattler, Walter A.
Chief Advisor of R&D and Director
-
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
